News on GlaxoSmithKline (Ticker: GSK) continually updated from thousands of sources around the net.
1 hr ago | TheStreet.com
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
3 hrs ago | Live Charts
British drug giant GlaxoSmithKline may spin off its consumer health division as it tries to get to grips with increasing competition for its drugs and Chinese bribery allegations, it was reported on Monday.
Investors dumped shares of Theravance last week, sending the stock down 18% to $22.94, after GlaxoSmithKline, which distributes Theravance's flagship pulmonary-disorder treatments, reported that sales of the products fell dramatically below expectations in the latest quarter.
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie ( AbbVie tops estimates in the second quarter AbbVie released its second-quarter results this morning, posting an Adjusted EPS of $0.82 on $4.926 billion in revenue.
In this 2008 file photo, signage is pictured on the company headquarters of GlaxoSmithKline in west London REUTERS/Toby Melville LONDON, July 24 - GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's ... (more)
Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business.
U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales .
GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for children in Africa.
Ligand Partner GSK Announces Record Quarterly Promactaa /Revoladea Revenue of $92 Million Strong quarterly growth driven by sales in US, EU and Emerging Markets SAN DIEGO-- --Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline plc has announced global revenue for Promactaa /Revoladea for the second quarter ended ... (more)
GlaxoSmithKline is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.
Good afternoon, welcome to today's call to everybody. GSK's performance in the second quarter provides evidence of the very significant changes are taking place in the Group's portfolio.
New Chief Executive of GlaxoSmithKline, Andrew Witty, poses for photographers outside the company headquarters in west London July 21, 2008.
Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline , said in an interview with Reuters on Wednesday.
The Pharmaceutical ETF is seeing unusually high volume in afternoon trading Wednesday, with over 377,000 shares traded versus three month average volume of about 101,000.
According to sources, the downturn can be attributed to the company's plans to delay the release of its highly anticipated title, Battlefield: Hardline .
Updated: Mon Jul 28, 2014 06:54 am
Copyright © 2014 Topix LLC